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ABSTRACT
Background The optimal antiretroviral treatment
for patients who have human immunodeficiency virus
(HIV) viremia despite treatment with nucleoside re-
verse-transcriptase inhibitors (nucleoside analogues)
remains uncertain. We studied treatment with regi-
mens that combined two nucleoside analogues, at
least one of which was new, with the protease inhib-
itor nelfinavir, the nonnucleoside reverse-transcriptase
inhibitor efavirenz, or both.
Methods The study included 195 patients who had
been treated with nucleoside analogues only, and had
a plasma HIV type 1 (HIV-1) RNA level of at least 500
copies per milliliter. Patients were randomly assigned
to receive, in addition to two nucleoside analogues,
nelfinavir, efavirenz, or nelfinavir plus efavirenz. The
primary end point was a plasma HIV-1 RNA level of
less than 500 copies per milliliter at week 16. A sec-
ondary end point was the composite of the HIV-1
RNA levels measured at weeks 40 and 48.
Results At week 16 and at weeks 40 and 48, the
proportions of patients in whom a plasma HIV-1 RNA
level of less than 500 copies per milliliter was achieved
were, respectively, 81 percent and 74 percent in the
nelfinavir-plus-efavirenz group, 69 percent and 60 per-
cent in the efavirenz group, and 64 percent and 35
percent in the nelfinavir group. Quadruple therapy re-
sulted in a higher rate of viral suppression in both
the short term (P=0.03) and the long term (P=0.001)
than did triple therapy with nelfinavir. Triple therapy
with efavirenz conferred a higher rate of long-term
suppression than triple therapy with nelfinavir (P=
0.004). Quadruple therapy also achieved a higher rate
of virologic suppression than triple therapy with efav-
irenz (P=0.008).
Conclusions In HIV-infected patients previously
treated with nucleoside analogues, treatment with
nelfinavir plus efavirenz and at least one new nucle-
oside analogue achieves a higher rate of viral suppres-
sion than do regimens with nucleoside analogues and
nelfinavir or efavirenz alone. (N Engl J Med 2001;345:
398-407.)
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N patients infected with the human immuno-
deficiency virus (HIV), whether or not they have
previously taken nucleoside reverse-transcriptase
inhibitors (nucleoside analogues), regimens con-
taining HIV-protease inhibitors1-4 have been shown to
suppress viral replication better than therapy with two
nucleoside analogues.5-7 Therapy with nonnucleoside
I
reverse-transcriptase inhibitors8-10 can achieve durable
suppression in patients who have not yet been treat-
ed with nucleoside analogues.
Although response rates to protease inhibitors or
nonnucleoside reverse-transcriptase inhibitors of 70
to 90 percent have been described in such patients,
the response rates are lower (45 to 80 percent) in pa-
tients who have already been treated with nucleoside
analogues.4,11 The optimal use of new antiretroviral
treatments for the latter group of patients is not well
defined. We undertook a trial to evaluate whether a
protease inhibitor, nelfinavir, or a nonnucleoside re-
verse-transcriptase inhibitor, efavirenz, or the combi-
nation of the two, along with two nucleoside ana-
logues, at least one of which was new to the patient,
would lead to the greatest reduction in the plasma
viral load in patients who had undergone extensive
previous treatment with nucleoside analogues.
METHODS
Study Design and Patients
The AIDS Clinical Trials Group (ACTG) 30212 and ACTG 30313
“rollover” studies that followed the ACTG 175 study14 were ran-
domized, partially blinded trials in which regimens of new nucleo-
side analogues or stavudine monotherapy were evaluated in patients
who had received zidovudine alone, zidovudine plus didanosine,
zidovudine plus zalcitabine, or didanosine monotherapy while par-
ticipating in the ACTG 175 study (Fig. 1). In the year before their
entry into the current study, patients who had received therapy
with nucleoside analogues exclusively for a median of 5.6 years
continued to receive the nucleoside-analogue regimens to which
they had been assigned in ACTG 302 or 303.
The ACTG 364 study was a phase 2, randomized, multicenter,
partially double-blind, three-group trial that compared nelfinavir,
efavirenz, and nelfinavir plus efavirenz, in combination with open-
label dual-nucleoside therapy, in patients with plasma HIV RNA
levels of at least 500 copies per milliliter at screening. The ran-
domization was stratified according to the treatment patients had
received in the ACTG 302 or 303 study. The primary outcome
measure, the short-term change in the plasma levels of HIV type 1
(HIV-1) RNA, was evaluated in terms of the proportion of pa-
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tients with plasma HIV-1 RNA levels of less than 500 copies per
milliliter and in terms of the change in the plasma HIV-1 RNA
level from base line to week 16. The secondary outcome measures
included the long-term effect on HIV-1 RNA levels as of weeks 40
and 48, the time to virologic failure (defined as a confirmed plas-
ma HIV-1 RNA level of at least 2000 copies per milliliter at week
16 or later), and the short- and long-term effects on the CD4 cell
count. Adverse events and any newly acquired immunodeficiency
syndrome (AIDS)–defining events were graded according to the
rating scale of the ACTG.15
Patients were recruited from 24 AIDS Clinical Trials Units and
5 regional units of the National Hemophilia Foundation in the
United States and Puerto Rico, and they continued to receive their
designated nucleoside-analogue therapy until enrollment. None of
the patients had previously received a nonnucleoside reverse-trans-
criptase inhibitor or a protease inhibitor. The study was approved
by the institutional review boards of the participating institutions,
and all patients provided written informed consent.
The patients were randomly assigned to receive one of three
treatments in a double-blind fashion: nelfinavir (750 mg three times
daily), efavirenz (600 mg once daily), or nelfinavir (750 mg three
times daily) plus efavirenz (600 mg once daily). Each patient was
also assigned to receive one of three regimens of open-label nu-
cleoside analogues: didanosine, 200 mg twice daily, plus lamivudine,
150 mg twice daily; didanosine, 200 mg twice daily, plus stavudine,
40 mg twice daily; or stavudine, 40 mg twice daily, plus lamivu-
dine, 150 mg twice daily. These assignments were made on the ba-
sis of the treatment the patient had received in the ACTG 302 or
303 study; these regimens were selected so that each patient re-
ceived at least one and if possible two new nucleoside analogues
(Fig. 1). Patients who had received stavudine in a previous ACTG
study were assigned to receive didanosine plus lamivudine; those
who had received zidovudine plus lamivudine were assigned to re-
ceive didanosine plus stavudine; those who had received zidovudine
plus didanosine were assigned to receive stavudine plus lamivudine;
those who had received zidovudine plus zalcitabine were assigned
to receive stavudine plus lamivudine; those who had received zido-
vudine plus zalcitabine plus lamivudine were assigned to receive
didanosine plus stavudine; and those who had received zidovudine
plus didanosine plus lamivudine were divided into two groups, one
of which was assigned to receive didanosine plus stavudine and the
other stavudine plus lamivudine. For patients who weighed less than
60 kg, didanosine was administered in a dose of 125 mg twice
daily and stavudine in a dose of 30 mg twice daily.
Monitoring and Enrollment
Clinical assessments of all patients were performed, their plasma
HIV-1 RNA levels and CD4 counts were measured, and routine
laboratory monitoring was conducted before they entered the study,
at the time of entry, at weeks 4, 8, 12, 16, and 24, and every
8 weeks thereafter. An executive summary of the week 16 results
was released on May 11, 1998; the study was not modified.
Plasma HIV-1 RNA Measurements
Plasma HIV-1 RNA levels were measured through week 48 with
a quantitative assay (Amplicor, Roche Diagnostic) with a lower lim-
it of quantitation of 500 copies per milliliter. Plasma samples that
contained fewer than 500 copies per milliliter were retrospectively
analyzed with the use of an ultrasensitive assay (Roche Diagnos-
tic) with a lower limit of quantitation of 50 copies per milliliter.
Figure 1. Previous Treatment Assignment, Eligibility Criteria, and Treatments of Patients in the AIDS Clinical Trials Group (ACTG)
364 Study.
The 195 patients in the ACTG 364 study had previously undergone randomization and been followed in the ACTG 175 trial as well
as in the ACTG 302 study or the ACTG 303 study. ZDV denotes zidovudine, ddI didanosine, ddC zalcitabine, d4T stavudine, 3TC
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Genotypic Testing
Retrospective genotyping was performed on base-line plasma
samples from 140 patients with at least one HIV-1 RNA meas-
urement of more than 2000 copies per milliliter. HIV-1 RNA was
extracted from plasma, and nested polymerase-chain-reaction am-
plification was used to generate a 1.3-kb fragment encompassing
protease and the first 750 nucleotides of reverse transcriptase.16 Se-
quences were compared with the HIV-1 clade B consensus sequence
(Los Alamos National Laboratory data base), and differences in the
amino acid sequence, including positions that contained a mixture
of wild-type and mutant residues, were classified as mutations.16-19
Phylogenetic analysis of the HIV-1 RNA sequence was used to
verify the lack of cross-contamination.
Statistical Analysis
Primary efficacy was assessed on the basis of the plasma HIV-1
RNA level. The means of the values obtained before and at the
initiation of study treatment were used as the base-line log-trans-
formed HIV-1 RNA level and CD4 cell count; HIV-1 RNA levels
lower than 500 or higher than 750,000 copies per milliliter were
replaced by these limits, respectively, before the base-line mean was
calculated. If a week 16 measurement of the plasma HIV-1 RNA
level or CD4 cell count was not available, the week 24 or week 12
value was used. Patients with missing values at weeks 12, 16, and
24 or at weeks 40 and 48 were excluded from the analysis of week
16 or weeks 40 and 48, respectively. The plasma HIV-1 RNA level
for weeks 40 and 48 was considered to be at 500 (or 50 by the
ultrasensitive assay) copies per milliliter if the HIV-1 RNA level at
either week 40 or week 48 was at least 500 (or 50) copies per mil-
liliter. The CD4 cell counts for weeks 40 and 48 were averaged.
Comparisons of the degree of suppression of HIV-1 RNA
achieved with the various treatments were performed with tests
of proportions, stratified according to the treatment received in the
ACTG 302 or 303 study (Cochran–Mantel–Haenszel test). The
exact 95 percent confidence intervals for the proportions were com-
puted under the assumption that there would be a binomial dis-
tribution. Changes in the CD4 cell count were compared by means
of the Kruskal–Wallis test; the 95 percent confidence intervals for
the median changes were based on order statistics20; the Wilcoxon
signed-rank test was used to assess whether the CD4 cell counts
had increased from base line. The times to various outcomes were
estimated according to the Kaplan–Meier method and compared
by means of the stratified log-rank test (stratified according to the
treatment received in ACTG 302 or 303). The occurrence of vi-
rologic failure was determined on the basis of the time to a con-
firmed HIV-1 RNA level of at least 2000 (or 200 by the ultrasen-
sitive assay) copies per milliliter at week 16 or later; confirmation
was defined as two consecutive measures above the threshold. Data
for subjects without virologic failure were censored at the time of
the last HIV-1 RNA measurement, at or after week 16. Logistic-
regression analysis was used to assess the associations between short-
term suppression of HIV-1 RNA (at week 16) and long-term sup-
pression (at weeks 40 and 48) and various base-line factors; odds
ratios were used to describe the size of the effects. Fisher’s exact test
was used to compare the proportions from the genotypic analysis.
One patient who never received the study treatment and had no
follow-up data was excluded from all analyses. The data for the re-
maining patients, including all available follow-up data through week
52, were analyzed according to the intention-to-treat principle. Ad-
verse events were evaluated and analyzed through week 56, but
data on adverse events in each patient were censored 8 weeks after
the permanent discontinuation of treatment in that patient. P values
for pairwise comparisons are two-tailed and are unadjusted for mul-
tiple comparisons.
RESULTS
Enrollment and Base-Line Characteristics
A total of 196 patients were randomly assigned to
treatment groups between July and September 1997.
The patient who did not receive the assigned treat-
ment and for whom no follow-up data were available
was excluded from the analyses. Of the remaining 195
patients, 66 were randomly assigned to the nelfinavir
group, 65 to the efavirenz group, and 64 to the nelfin-
avir-plus-efavirenz group. The three treatment groups
were well balanced with regard to base-line charac-
teristics (Table 1). Most patients (143 of 195 patients
[73 percent]) received two new nucleoside analogues;
52 patients (27 percent) who had received zidovu-
dine, didanosine, and lamivudine in the ACTG 302
or 303 study received only one new nucleoside ana-
logue (Fig. 1). The three treatment groups were bal-
anced with regard to the distribution of the assigned
regimens of nucleoside analogues at study entry.
Follow-up and Treatment Status
There was a minimal dropout rate from the study.
A total of 11 patients (6 percent) had dropped out
of the study (9 patients) or died (2 patients) by week
52, and the dropout rate did not vary according to
treatment group. A total of 33 patients (17 percent)
permanently discontinued the study treatment during
the 52 weeks of follow-up. Most of these patients dis-
continued treatment because of protocol-defined vi-
rologic failure (in 20 patients [61 percent]) or adverse
clinical events. The observed rate of permanent dis-
continuation of the study treatment was 29 percent
(19 of 66 patients) in the nelfinavir group, 11 percent
(7 of 65 patients) in the efavirenz group, and 11 per-
cent (7 of 64 patients) in the nelfinavir-plus-efavirenz
group (P=0.01 for the three-way comparison). Vi-
rologic failure accounted for the permanent discon-
tinuation of the study drug in 15 of the 19 patients
who discontinued treatment in the nelfinavir group
(79 percent), 5 of the 7 in the efavirenz group (71
percent), and none of the 7 in the nelfinavir-plus-
efavirenz group.
Short-Term Effects on Viral Load
At week 16, the proportions of patients with plas-
ma HIV-1 RNA levels of less than 500 copies per
milliliter by the standard assay and less than 50 copies
per milliliter by the ultrasensitive assay, respectively,
were 81 percent (51 of 63) and 67 percent (42 of 63)
in the nelfinavir-plus-efavirenz group, 69 percent (45
of 65) and 62 percent (40 of 65) in the efavirenz
group, and 64 percent (42 of 66) and 39 percent
(26 of 66) in the nelfinavir group (Fig. 2). With the
quadruple therapy there was a higher rate of suppres-
sion of the viral load than with triple therapy with nel-
finavir, according to both the standard HIV-1 RNA
assay (P=0.03) and the ultrasensitive assay (P=
0.001); with triple therapy with efavirenz there was a
better virologic response than with triple therapy with
nelfinavir, according to the ultrasensitive assay (P=
0.01). There was no significant difference between the
efavirenz group and the nelfinavir-plus-efavirenz group
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in the rate of suppression of HIV-1 RNA at week 16
(P=0.11 with the standard assay and P=0.54 with the
ultrasensitive assay).
Long-Term Effects on Viral Load
The highest rates of response to treatment at weeks
40 and 48 occurred in the nelfinavir-plus-efavirenz
group (Fig. 2), in which the rate of suppression of
HIV-1 RNA was higher than that in the nelfinavir
group according to both the standard and the ultra-
sensitive assays (P=0.001 for both comparisons). Sim-
ilarly, patients in the efavirenz group had significantly
greater reductions of viral load than did those in the
nelfinavir group according to both the standard assay
(P=0.004) and the ultrasensitive assay (P=0.008)
(Fig. 2). At weeks 40 and 48, the patients in the nel-
finavir-plus-efavirenz group had a higher rate of sup-
pression than those in the efavirenz group according
to the ultrasensitive assay (P=0.008); a similar pat-
tern was seen with the standard assay, but the differ-
ence was not statistically significant (P=0.09).
Time to Virologic Failure
The duration of response, defined as the time from
base line to virologic failure (defined as a confirmed
plasma HIV-1 RNA level of at least 2000 copies per
milliliter according to the standard assay or at least
200 copies per milliliter according to the ultrasensi-
tive assay at week 16 or later) was significantly longer
among the patients in the nelfinavir-plus-efavirenz
group than among those in the nelfinavir group (P<
0.001) (Fig. 3). By week 48, virologic failure as con-
firmed by the standard assay had occurred in 30 pa-
tients in the nelfinavir group, 20 in the efavirenz
group, and 11 in the nelfinavir-plus-efavirenz group;
virologic failure as confirmed by the ultrasensitive assay
had occurred in 42, 27, and 13 patients, respectively.
Effects on CD4 Cell Count
A significant increase in the CD4 cell count was
sustained, with a median increase from base line to
week 16 of 70 cells per cubic millimeter (all groups
combined; P<0.001; 95 percent confidence inter-
val, 52 to 93) and a median increase from base line
to weeks 40 and 48 of 94 cells per cubic millimeter
(P<0.001; 95 percent confidence interval, 80 to 112)
(Fig. 4). There were no significant short- or long-
term differences in the changes in CD4 cell count
among the three treatment groups. Significantly high-
er median increases in the CD4 cell count at weeks
40 and 48 occurred in patients with HIV-1 RNA
levels of less than 500 copies per milliliter (a median
increase of 113 cells per cubic millimeter) than in those
with HIV-1 RNA levels of 500 copies per milliliter
or more (a median increase of 66 cells per cubic mil-
limeter) (P=0.003).
Predictors of Viral Suppression at Weeks 40 and 48
Multivariate logistic-regression models were con-
structed in which the patients were recategorized ac-
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Figure 2. Percentage of Patients with Plasma HIV-1 RNA Levels of Less Than 500 Copies per Milliliter
According to the Standard Assay (Panel A) and Less Than 50 Copies per Milliliter According to the
Ultrasensitive Assay (Panel B).
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Figure 3. Kaplan–Meier Estimates of the Time to Virologic Failure.
Virologic failure was defined as a plasma HIV-1 RNA level of at least 2000 copies per milliliter according to the standard assay (Panel
A) and at least 200 copies per milliliter according to the ultrasensitive assay (Panel B). In Panel A, the stratified log-rank P values
were as follows: 0.14 for the comparison of nelfinavir with efavirenz, <0.001 for the comparison of nelfinavir with nelfinavir plus
efavirenz, and 0.06 for the comparison of efavirenz with nelfinavir plus efavirenz. In Panel B, the stratified log-rank P values were
as follows: 0.04 for the comparison of nelfinavir with efavirenz, <0.001 for the comparison of nelfinavir with nelfinavir plus efavirenz,
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cording to whether they received lamivudine for the
first time in the ACTG 364 study. The base-line
HIV-1 RNA level (P<0.001), treatment with la-
mivudine as a new nucleoside analogue (P<0.001),
and the treatment assignment in the current trial (P<
0.001) were significant independent predictors of vi-
ral suppression (defined as an HIV-1 RNA level of
less than 500 copies per milliliter and less than 50
copies per milliliter according to the two different
assays) at weeks 40 and 48 (Table 2). Early decreases
in the plasma HIV-1 RNA level were evaluated to
determine whether they were predictive of the chang-
es in viral load at weeks 40 and 48. After adjustment
for treatment assignment, an HIV-1 RNA level of less
than 50 copies per milliliter at week 16 was highly
predictive of viral suppression at weeks 40 and 48
(P<0.001; odds ratio, 9.77; 95 percent confidence
interval, 4.63 to 22.19).
Base-Line Genotypic Mutations and Virologic Outcome
Previous exposure to drugs and mutations in the
reverse-transcriptase gene at base line were examined
retrospectively in 140 patients with available base-line
genotypic data. High-level resistance to nucleoside
reverse-transcriptase inhibitors was defined by the
presence of five or more of the specified reverse-tran-
scriptase mutations or a mutation or insertion known
to confer multinucleoside resistance (Table 3).
Among the patients in whom genotyping was com-
pleted, the response rates within the treatment groups
at weeks 40 and 48 were similar to those in the over-
all study population. In the group with five or more
reverse-transcriptase mutations or a known genetic
marker of multinucleoside resistance at base line,
HIV-1 RNA levels of less than 50 copies per millili-
ter were achieved at weeks 40 and 48 in 19 percent
of the patients in the nelfinavir group (4 of 21) and
30 percent of those in the efavirenz group (3 of 10),
as compared with 75 percent of the patients in the
nelfinavir-plus-efavirenz group (9 of 12) (Table 3).
There was a significant difference between the nel-
finavir group and the nelfinavir-plus-efavirenz group
in long-term viral suppression among patients with
high-level reverse-transcriptase resistance (P=0.003),
and there was a trend toward significance in the dif-
ference between the efavirenz group and the nelfin-
avir-plus-efavirenz group (P=0.08).
Adverse Events and Clinical Disease Progression
There was no significant difference among the three
treatment groups with respect to the time to the de-
velopment of the first grade 3 (severe) or grade 4 (life-
threatening) signs or symptoms, which occurred in
a total of 36 patients (18 percent) — 12 patients in
the nelfinavir group, 10 in the efavirenz group, and
14 in the nelfinavir-plus-efavirenz group (P>0.3 for
all pairwise comparisons). The most frequent grade
3 or 4 signs or symptoms reported were aches, pain,
or discomfort (in 13 patients [7 percent]) and diarrhea
or loose stools (in 7 patients [4 percent]). A grade 3
Figure 4. Median Changes in CD4 Cell Count from Base Line.
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or 4 rash developed in only three patients (2 per-
cent). Grade 2 (moderate) peripheral neuropathy de-
veloped in six patients (3 percent).
There were no significant differences among the
three treatment groups in the time to development of
grade 3 or 4 laboratory abnormalities, which occurred
in a total of 58 patients (30 percent) — 23 patients
in the nelfinavir group, 17 in the efavirenz group, and
18 in the nelfinavir-plus-efavirenz group (P>0.3 for
all pairwise comparisons). The most common labo-
ratory abnormalities were creatine kinase elevations
(in 23 patients [12 percent]) and elevated triglycer-
ide levels (in 21 patients [11 percent]).
During 52 weeks of follow-up, an AIDS-defining
lymphoma developed in one patient in the nelfinavir-
plus-efavirenz group (3 weeks after the study treat-
ment began). Two patients (one in the nelfinavir group
and one in the efavirenz group) died, but their deaths
were not attributed to HIV infection.
DISCUSSION
We found that in HIV-infected patients who have
previously undergone prolonged therapy with nucle-
oside analogues, quadruple therapy with nelfinavir,
efavirenz, and two nucleoside analogues, of which at
least one was new, achieved higher rates of viral sup-
pression (a plasma HIV-1 RNA level of less than 50
copies per milliliter) at weeks 40 and 48 and signif-
*CI denotes confidence interval.
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HIV-1 RNA level (per log10 
decrease)
3.21 (2.00–5.41) <0.001 2.30 (1.47–3.73) <0.001
Lamivudine as new nucleoside 
analogue at study entry
7.40 (3.34–17.72) <0.001 3.34 (1.64–7.04) <0.001
*Viral suppression was defined as a plasma HIV-1 RNA level of less than 50 copies per milliliter
according to the ultrasensitive assay. Nucleoside reverse-transcriptase mutations at codons 41, 65, 67,
69, 70, 74, 75, 184, 210, 215, and 219 were considered evidence of resistance to nucleoside reverse-
transcriptase (RT) inhibitors.17 Patients were considered to have high-level resistance if they had five
or more of these cardinal mutations or if they had one of the following known markers of multinu-
cleoside resistance (MNR): a Q151M mutation in the RT gene, accompanied by A62V, V75I, F77L,
and F116Y mutations, or an amino acid insertion at codon 69.17 Six sequences with MNR had an
insertion at codon 69. These mutations are present in fewer than 1 percent of the sequences obtained
from persons who have not been treated with antiretroviral drugs, are associated with in vitro resist-
ance, and occur among patients in whom combination antiretroviral therapy has failed.17-19
TABLE 3. BASE-LINE GENOTYPIC MUTATIONS AND VIRAL SUPPRESSION 





PATIENTS WITH 0–4 
RT MUTATIONS AND 
NO KNOWN GENETIC 
MARKER OF MNR
PATIENTS WITH 5 OR 
MORE RT MUTATIONS 
OR A KNOWN GENETIC 
MARKER OF MNR
no. with suppression/total no. with genotypic data (%)
Nelfinavir 11/51 (22) 7/30 (23) 4/21 (19)
Efavirenz 17/46 (37) 14/36 (39) 3/10 (30)
Nelfinavir plus efavirenz 27/43 (63) 18/31 (58) 9/12 (75)
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icantly more durable suppression, measured in terms
of time to failure (a confirmed plasma HIV-1 RNA
level of at least 200 copies per milliliter), than triple
therapy with either nelfinavir or efavirenz and new
nucleoside analogues. The response rates in the nel-
finavir-plus-efavirenz group were similar to those re-
ported in the DMP 266-020 study21 and a pediatric
clinical trial22 that evaluated efavirenz in combination
with a protease inhibitor plus nucleoside analogues
in patients who had previously been treated with nu-
cleoside analogues.
Triple therapy with efavirenz conferred greater and
more durable viral suppression than triple therapy with
nelfinavir. We cannot fully explain the inferior viral
suppression observed in the nelfinavir group as com-
pared with the nelfinavir-plus-efavirenz group and the
efavirenz group in this study. In the subgroup in
whom genotyping was performed, there were simi-
larly low rates of viral suppression in those with zero
to four reverse-transcriptase mutations (23 percent
of the nelfinavir group) as in those with five or more
reverse-transcriptase mutations at base line or the pres-
ence of mutations known to confer multinucleoside
resistance (19 percent of the nelfinavir group). The
distribution of reverse-transcriptase genotypes in this
subgroup does not fully explain the inferior virolog-
ic outcomes in the nelfinavir group, since the response
rate found in each treatment group in the subgroup
analysis was similar to that found in that treatment
group in the primary analysis of the entire study pop-
ulation.
The pharmacokinetic profiles of the study drugs
and adherence to the treatment regimens were not
evaluated in this study, which precludes any assess-
ment of whether adequate exposure to nelfinavir was
achieved in this population of patients. The patients in
the nelfinavir group had CD4 cell responses that were
similar to those observed in the other two groups,
which suggests that partially suppressive regimens in
patients who have already undergone treatment with
nucleoside analogues may still confer clinical benefit by
affording substantial increases in the CD4 cell count.
Extensive previous treatment with nucleoside an-
alogues that has led to the development of muta-
tions associated with resistance to zidovudine may
result in hypersusceptibility to nonnucleoside reverse-
transcriptase inhibitors.23,24 This phenomenon was ob-
served in a preliminary phenotypic analysis conduct-
ed at base line in 130 patients in the present study:
37 percent of isolates of virus from these patients were
hypersusceptible to efavirenz (i.e., the concentration
required to inhibit viral replication by 50 percent
[IC50] was <0.4 of the IC50 for a wild-type reference
strain). Although hypersusceptibility to nonnucleoside
reverse-transcriptase inhibitors at base line was not
found to be highly predictive of long-term viral sup-
pression in our exploratory analyses, the continued use
of nucleoside analogues to maintain hypersuscepti-
bility in salvage regimens may be a treatment strategy
that warrants further evaluation.
Although we did not prospectively evaluate geno-
typing at base line, patients who have been exten-
sively exposed to nucleoside analogues and who have
viral rebound may benefit from genotyping if two
new classes of drugs are introduced when nucleoside
resistance is confirmed. Although conserving some
classes of treatment for later use is an important con-
sideration in patients in whom virologic failure has
occurred once or twice, the selection of inadequately
potent and partially suppressive alternative regimens
may result in the evolution of drug resistance in blood
and other tissue compartments. The benefits of using
additional classes of potent agents, as we did in the
nelfinavir-plus-efavirenz group, with the goal of sup-
pressing viral replication to below the limit of detec-
tion and of restoring the immune response must be
weighed against the potential risks of incurring new
or long-term toxic effects and limiting future treat-
ment options.
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